医学
阿糖胞苷
内科学
临床试验
髓系白血病
药理学
胃肠病学
肿瘤科
作者
Michael Kruszewski,Claudia Schmoor,Tobias Berg,Usama‐Ur Rehman,Marcus M. Schittenhelm,Katharina S. Götze,Andrea Kündgen,Caroline Pabst,Tobias Ma,Anna Frey,Julia Stomper,Dietmar Pfeifer,Eric Metzger,Johannes Jung,Kevin Moschallski,Johanna Thomas,Gesine Bug,Justus Duyster,Manfred Jung,Roland Schüle
摘要
ABSTRACT The treatment of elderly, nonfit acute myeloid leukemia (AML)/MDS patients with relapsed/refractory (R/R) disease remains challenging. As histone demethylase LSD1 (KDM1A) is a rational therapeutic target in AML, we conducted a phase I trial (“rolling‐six design”) with the LSD1 inhibitor tranylcypromine (TCP, dose levels [DL] 20, 40, 60, 80 mg p.o. d1‐28) combined with fixed‐dose ATRA (45 mg/m 2 p.o. d10‐28) and low‐dose cytarabine (LDAC, 40 mg s.c. d1‐10). The primary endpoint was dose‐limiting toxicity (DLT) in the first 28 days of treatment. The aim was the determination of the maximum tolerated TCP dose (MTD). Twenty‐three patients with AML and 2 with MDS were accrued. TCP was administered for a median of 39.5 days (range: 11–228). No DLTs were observed at any DL; MTD could not be established. No differentiation syndrome occurred. Two patients attained a PR; SD was achieved in 10 of 22 evaluable patients. Median OS was 62 days (range: 14–325). Accompanying studies included pharmacokinetics, serial determinations of fetal hemoglobin (HbF), detection of CD38 upregulation with treatment, as well as transcriptome changes in purified blood blasts over time. In conclusion, the combination of TCP with ATRA and LDAC was well feasible, even at the highest DL. Hence, studies with more potent LSD1 inhibitors appear warranted. Trial Registration: German Clinical Trials Register (DRKS): DRKS00006055. For further Information see https://drks.de/search/en/trial/DRKS00006055
科研通智能强力驱动
Strongly Powered by AbleSci AI